Biotech Values

[urche]

Is this suggestive of Tysabri?



From GTCB PR today:
The first quarter of 2005 revenues were primarily due to continuation of the activities with Merrimack Pharmaceuticals, funding of the malaria vaccine program by the National Institute of Allergy and Infections Diseases, and completion of the programs with Elan Pharmaceuticals.

To my knowledge, GTCB and Elan have disclosed a collaboration on an undisclosed protein. Considering the withdrawal of Tysabri from the market, and the disclosure above, I wonder if GTCB had been working on making Tysabri.

Urche